The agency recommends against using current tests to screen for the disease and relying on the test results to make treatment decisions. Instead, the FDA recommends women talk with their physicians about ways to decrease ovarian cancer risk and for physicians to refrain from using the tests. In addition, the agency said physicians should refer women at high risk for ovarian cancer to genetic counselors or gynecologic oncologists.
Current screenings may lead to false positives and unnecessary treatment, or false negatives and delayed treatment, the alert said.
More articles about healthcare quality:
NIH, HHS offer up to $20M in prizes for antibiotic resistance-combating solutions
Pennsylvania reports its 1st sexually transmitted Zika case
Glendale Adventist Medical Center’s ban on vaginal-breech deliveries sparks activist protests
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
